Cargando…
Author response to Colle et al
The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, w...
Autores principales: | Fucà, Giovanni, Corti, Francesca, Pietrantonio, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231051/ https://www.ncbi.nlm.nih.gov/pubmed/34162717 http://dx.doi.org/10.1136/jitc-2021-003138 |
Ejemplares similares
-
Letter to the Editor from Colle et al
por: Colle, Raphael, et al.
Publicado: (2021) -
Author response to Cunha et al
por: Colen, Rivka R, et al.
Publicado: (2021) -
Authors’ response to comments from Nachman KE et al.
por: O’Connor, Annette M., et al.
Publicado: (2017) -
Commentary: A Comment on Qi et al.—Authors’ Reply
por: Qi, X. Sharon, et al.
Publicado: (2012) -
Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
por: Ziogas, Dimitrios C, et al.
Publicado: (2021)